Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Pollak

Showing results (21-30 of 236) with videos related to

Pageof 24
Sort By:
Aging Cell|March 14, 2009
Aging, IGF-1, and dietMichael Pollak
Cell Metabolism|May 7, 2009
Do cancer cells care if their host is hungry?Michael Pollak
Current Drug Targets|August 12, 2009
Clinical development of inhibitors of the insulin-like growth factor receptor in oncologyAntonio Gualberto, Michael Pollak
Lancet (London, England)|July 31, 2002
Risk of cancer after growth-hormone treatmentEdward Giovannucci, Michael Pollak
Cancer & Metabolism|November 28, 2013
Why Cancer & Metabolism? Why now?Chi Van Dang, Michael Pollak
Cancer Research|December 25, 2002
Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cellsRandy J Levitt, Michael Pollak
International Journal of Cancer|December 4, 2003
Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cellsYuhong Lu, Xiaolin Zi, Michael Pollak
Cancer Prevention Research (Philadelphia, Pa.)|April 3, 2012
Metformin and hepatic carcinogenesisMichael Pollak, Ana M Gonzalez-Angulo
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|December 28, 2002
Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cellsAnne Camirand, Yuhong Lu, Michael Pollak
Biochimica Et Biophysica Acta. Molecular Cell Research|May 14, 2021
The role of GSK3 in metabolic pathway perturbations in cancerDavid Papadopoli, Michael Pollak, Ivan Topisirovic
Pageof 24

Showing results (21-30 of 236) with videos related to

Sort By:
Pageof 24
Aging Cell|March 14, 2009
Aging, IGF-1, and dietMichael Pollak
Cell Metabolism|May 7, 2009
Do cancer cells care if their host is hungry?Michael Pollak
Current Drug Targets|August 12, 2009
Clinical development of inhibitors of the insulin-like growth factor receptor in oncologyAntonio Gualberto, Michael Pollak
Lancet (London, England)|July 31, 2002
Risk of cancer after growth-hormone treatmentEdward Giovannucci, Michael Pollak
Cancer & Metabolism|November 28, 2013
Why Cancer & Metabolism? Why now?Chi Van Dang, Michael Pollak
Cancer Research|December 25, 2002
Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cellsRandy J Levitt, Michael Pollak
International Journal of Cancer|December 4, 2003
Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cellsYuhong Lu, Xiaolin Zi, Michael Pollak
Cancer Prevention Research (Philadelphia, Pa.)|April 3, 2012
Metformin and hepatic carcinogenesisMichael Pollak, Ana M Gonzalez-Angulo
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|December 28, 2002
Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cellsAnne Camirand, Yuhong Lu, Michael Pollak
Biochimica Et Biophysica Acta. Molecular Cell Research|May 14, 2021
The role of GSK3 in metabolic pathway perturbations in cancerDavid Papadopoli, Michael Pollak, Ivan Topisirovic
Pageof 24